COMMUNIQUÉS West-GlobeNewswire

Press Release: Sanofi provides update on the regulatory submission for Sarclisa subcutaneous in the US
22/04/2026
Sanofi provides update on the regulatory submission for Sarclisa subcutaneous in the US Paris, April 22, 2026. The US Food and Drug Administration (FDA) has extended by up to three months the target action date for its [...]
Maze Therapeutics Announces $150 Million Registered Offering
22/04/2026
SOUTH SAN FRANCISCO, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE) today announced the pricing of its underwritten registered offering of 5,540,000 shares of its common stock at a [...]
Axomove lève 4 M€ pour accélérer la commercialisation de son dispositif médical numérique de prévention et de rééducation
22/04/2026
Axomove lève 4 M€ pour accélérer la commercialisation de son dispositif médical numérique de prévention et de rééducation Ce tour d’investissement de série A est co-dirigé par le Fonds Prévention Numérique, géré par [...]
Ojemda® approved in the European Union as the first targeted therapy in relapsed or refractory pediatric low-grade glioma regardless of BRAF alteration
22/04/2026
New treatment option for rare, life-altering pediatric brain tumors Less than 10% of new medicine approvals over the past five years have focused on pediatric diseases; Ojemda ® (tovorafenib) represents a rare [...]
Press Release: Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children
22/04/2026
Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children Expanded approval includes children aged one year and above with stage 2 T1D to delay the onset of stage 3 Tzield is the [...]
Elkedonia strengthens Board of Directors with appointment of Pierre d’Epenoux as Independent Chairman
22/04/2026
Appointment strengthens Elkedonia's governance as the company continues its development and prepares for its next phases of growth Pierre d’Epenoux is former CEO of ImCheck Therapeutics, a clinical-stage biotech immuno- [...]
Communiqué de presse : Tzield de Sanofi approuvé aux États-Unis pour retarder l’apparition du diabète de type 1 de stade 3 chez les jeunes enfants
22/04/2026
Tzield de Sanofi approuvé aux États-Unis pour retarder l’apparition du diabète de type 1 de stade 3 chez les jeunes enfants L'extension d'approbation inclut les enfants âgés d'un an et plus atteints de diabète de type 1 [...]
Ojemda® approuvé dans l’Union européenne comme première thérapie ciblée pour les enfants atteints de gliome pédiatrique de bas grade (pLGG), en rechute ou réfractaire, indépendamment de l’altération de BRAF
22/04/2026
 Nouvelle option thérapeutique pour des tumeurs cérébrales pédiatriques rares et potentiellement invalidantes Moins de 10 % des nouvelles autorisations de médicaments au cours des cinq dernières années ont porté sur des [...]
Elkedonia renforce son Comité stratégique avec la nomination de Pierre d'Epenoux comme Président indépendant
22/04/2026
Cette nomination renforce la gouvernance d'Elkedonia alors que la société poursuit son développement et prépare ses prochaines étapes de croissance Pierre d'Epenoux est l'ancien Président Directeur Général d'ImCheck [...]
RNK Health NAD+ Longevity Therapy Claims Evaluated: The Clinician-Guided NAD Injections & Medication Protocol
22/04/2026
An informational overview of how RNK Health structures its at-home NAD+ injection program for 2026, including telehealth eligibility, compounded medication protocols, pricing from $129/mo, and what to know about [...]
Ascentage Pharma to Present Data from Multiple Trials, Including Three Rapid Oral Presentations, at ASCO 2026
22/04/2026
ROCKVILLE, Md. and SUZHOU, China, April 21, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the [...]
Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting
22/04/2026
Single-dose of miv-cel achieved robust and durable improvements in mobility, reversed disability scores, and eliminated the need for chronic immunotherapies – outcomes not previously observed in SPS Data underscore [...]
pHemmePure Claims Evaluated: Feminine UTI Balance Formula for Vaginal pH Support by Board-Certified Urologist
22/04/2026
pHemmePure outlines its feminine balance supplement approach, full ingredient disclosure, and urinary tract wellness positioning for women over 35 seeking daily pH support in 2026 New York, NY, April 21, 2026 (GLOBE [...]
Roche’s fenebrutinib significantly reduced relapses versus standard of care to approximately one every 17 years in RMS
22/04/2026
Late-breaking Phase III FENhance 1 and 2 study results showed superiority of investigational fenebrutinib compared to teriflunomide in reducing relapses and brain lesions in relapsing multiple sclerosis (RMS) Both [...]
Triple Green Farms CBD Gummies Claims Evaluated: The Best CBD Gummy Formula on the Market Under Investigation
22/04/2026
A 2026 informational report on Triple Green Farms CBD Gummies' full spectrum hemp extract formula, how the endocannabinoid system works, what published CBD research supports, pricing and guarantee terms, and what adults [...]
Curiox Biosystems Signs Master Software License Agreement for Enterprise-Scale Pluto Code Deployment
22/04/2026
First master licensing framework for Pluto Code enables a global pharmaceutical organization to expand centrifuge-free automation across its liquid-handling infrastructure without repeated contracting WOBURN, Mass., [...]
Olema Oncology to Present Initial Clinical Data for OP-3136 at the 2026 ASCO Annual Meeting
21/04/2026
SAN FRANCISCO, April 21, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and [...]
Belite Bio Initiates Rolling Submission of New Drug Application to the U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease
21/04/2026
Belite expects to complete the new drug application submission in the second quarter of 2026 Rolling submission initiated under Breakthrough Therapy Designation SAN DIEGO, April 21, 2026 (GLOBE NEWSWIRE) -- Belite Bio [...]
Revolution Medicines to Present Updated Phase 1/2 Clinical Data for Daraxonrasib in First Line Metastatic Pancreatic Cancer Across Monotherapy and Combination Cohorts at the 2026 AACR Annual Meeting
21/04/2026
REDWOOD CITY, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today [...]

Pages